Emmanuelle Schindler
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Neurological disorders like chronic pain and Alzheimer’s are being studied for psychedelic therapy benefits, expanding research beyond traditional mental health applications. Current studies explore potential applications for neurorehabilitation.
Julia Bornemann, James Close, Joel Castellanos, Robin Carhart-Harris
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Psychedelic drugs may enhance creative thinking and empathy, supported by anecdotal reports and some scientific evidence. Studies show time- and construct-dependent effects on flexible cognition, with brain imaging linking changes
Natasha Mason
Psychedelics and 5-HT2A agonists show varying anti-inflammatory effects unrelated to their behavioral impact. Research identifies cellular mechanisms and aims to develop new compounds with targeted therapeutic properties.
Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.
Jennifer Danby
Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.
Tommaso Barba
Psychedelic compounds show promise for treating neuropsychiatric disorders, but limited patient access is a challenge. Non-hallucinogenic psychedelics, or neuroplastogens, are emerging as a potential solution to address concerns.
Psilocybin's therapeutic potential for various medical conditions is being explored, including pilot studies on Alzheimer's Disease and chronic Lyme Disease. Preliminary results and participant reports inform ongoing psilocybin-assisted treatments research.
Albert Garcia-Romeu
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.